FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083722579> ?p ?o ?g. }

• W2083722579 endingPage "177" @default.
• W2083722579 startingPage "172" @default.
• W2083722579 abstract "Purpose Combination therapy with aprepitant, serotonin receptor antagonist, and steroids improves the complete response rate of both acute and delayed chemotherapy-induced nausea and vomiting (CINV). However, it is not known whether ramosetron is suitable for administration in combination with aprepitant. Therefore, we conducted a multicenter, open-label, prospective, phase II study in order to assess the efficacy and tolerability of combination therapy with ramosetron, aprepitant, and dexamethasone (RAD) for prevention of cisplatin-based CINV in chemotherapy-naïve patients with solid cancers. Materials and Methods Forty-one patients with various solid cancers (31 male and 10 female; median age, 59 years) who received treatment with highly emetogenic chemotherapy (median cisplatin dose, 70 mg/m2; range 50 to 75 mg/m2) were enrolled in this study. Oral aprepitant (125 mg on day 1; 80 mg on days 2 and 3), intravenous ramosetron (0.6 mg on day 1), and oral dexamethasone (12 mg on day 1; 8 mg on days 2-4) were administered for prevention of CINV. Results The complete response (no emesisand retching and no rescue medication) rate was 94.9% in the acute period (24 hours post-chemotherapy), 92.3% in the delayed period (24-120 hours post-chemotherapy), and 92.3% in the overall period (0-120 hours). The absolute complete response (complete response plus no nausea) rate was 74.4% in the acute period, 51.3% in the delayed period, and 46.2% in the overall period. There were no grade 3 or 4 toxicities related to these antiemetic combinations. Conclusion RAD regimen is a safe and effective antiemetic treatment for prevention of CINV in patients receiving highly emetogenic chemotherapy. Key words: Aprepitant, Dexamethasone, Ramosetron, Chemotherapy-induced nausea and vomiting" @default.
• W2083722579 created "2016-06-24" @default.
• W2083722579 creator A5018855985 @default.
• W2083722579 creator A5023660159 @default.
• W2083722579 creator A5041556537 @default.
• W2083722579 creator A5042276732 @default.
• W2083722579 creator A5044201544 @default.
• W2083722579 creator A5044483735 @default.
• W2083722579 creator A5050867707 @default.
• W2083722579 creator A5073175278 @default.
• W2083722579 creator A5082124715 @default.
• W2083722579 creator A5084870834 @default.
• W2083722579 creator A5084955195 @default.
• W2083722579 creator A5091240913 @default.
• W2083722579 date "2013-09-30" @default.
• W2083722579 modified "2023-10-11" @default.
• W2083722579 title "A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naive Cancer Patients" @default.
• W2083722579 cites W1976163648 @default.
• W2083722579 cites W1997467714 @default.
• W2083722579 cites W1999536841 @default.
• W2083722579 cites W2023213594 @default.
• W2083722579 cites W2054514523 @default.
• W2083722579 cites W2067976131 @default.
• W2083722579 cites W2069354996 @default.
• W2083722579 cites W2074932840 @default.
• W2083722579 cites W2087393401 @default.
• W2083722579 cites W2105030925 @default.
• W2083722579 cites W2116682901 @default.
• W2083722579 cites W2120113475 @default.
• W2083722579 cites W2123267000 @default.
• W2083722579 cites W2134405107 @default.
• W2083722579 cites W2165395427 @default.
• W2083722579 doi "https://doi.org/10.4143/crt.2013.45.3.172" @default.
• W2083722579 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3804728" @default.
• W2083722579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24155675" @default.
• W2083722579 hasPublicationYear "2013" @default.
• W2083722579 type Work @default.
• W2083722579 sameAs 2083722579 @default.
• W2083722579 citedByCount "4" @default.
• W2083722579 countsByYear W20837225792014 @default.
• W2083722579 countsByYear W20837225792015 @default.
• W2083722579 crossrefType "journal-article" @default.
• W2083722579 hasAuthorship W2083722579A5018855985 @default.
• W2083722579 hasAuthorship W2083722579A5023660159 @default.
• W2083722579 hasAuthorship W2083722579A5041556537 @default.
• W2083722579 hasAuthorship W2083722579A5042276732 @default.
• W2083722579 hasAuthorship W2083722579A5044201544 @default.
• W2083722579 hasAuthorship W2083722579A5044483735 @default.
• W2083722579 hasAuthorship W2083722579A5050867707 @default.
• W2083722579 hasAuthorship W2083722579A5073175278 @default.
• W2083722579 hasAuthorship W2083722579A5082124715 @default.
• W2083722579 hasAuthorship W2083722579A5084870834 @default.
• W2083722579 hasAuthorship W2083722579A5084955195 @default.
• W2083722579 hasAuthorship W2083722579A5091240913 @default.
• W2083722579 hasBestOaLocation W20837225791 @default.
• W2083722579 hasConcept C126322002 @default.
• W2083722579 hasConcept C197934379 @default.
• W2083722579 hasConcept C2776694085 @default.
• W2083722579 hasConcept C2778375690 @default.
• W2083722579 hasConcept C2778573518 @default.
• W2083722579 hasConcept C2779924295 @default.
• W2083722579 hasConcept C2780401358 @default.
• W2083722579 hasConcept C2780574406 @default.
• W2083722579 hasConcept C2780580376 @default.
• W2083722579 hasConcept C2780852908 @default.
• W2083722579 hasConcept C2780884295 @default.
• W2083722579 hasConcept C42219234 @default.
• W2083722579 hasConcept C71924100 @default.
• W2083722579 hasConcept C90924648 @default.
• W2083722579 hasConceptScore W2083722579C126322002 @default.
• W2083722579 hasConceptScore W2083722579C197934379 @default.
• W2083722579 hasConceptScore W2083722579C2776694085 @default.
• W2083722579 hasConceptScore W2083722579C2778375690 @default.
• W2083722579 hasConceptScore W2083722579C2778573518 @default.
• W2083722579 hasConceptScore W2083722579C2779924295 @default.
• W2083722579 hasConceptScore W2083722579C2780401358 @default.
• W2083722579 hasConceptScore W2083722579C2780574406 @default.
• W2083722579 hasConceptScore W2083722579C2780580376 @default.
• W2083722579 hasConceptScore W2083722579C2780852908 @default.
• W2083722579 hasConceptScore W2083722579C2780884295 @default.
• W2083722579 hasConceptScore W2083722579C42219234 @default.
• W2083722579 hasConceptScore W2083722579C71924100 @default.
• W2083722579 hasConceptScore W2083722579C90924648 @default.
• W2083722579 hasIssue "3" @default.
• W2083722579 hasLocation W20837225791 @default.
• W2083722579 hasLocation W20837225792 @default.
• W2083722579 hasLocation W20837225793 @default.
• W2083722579 hasLocation W20837225794 @default.
• W2083722579 hasLocation W20837225795 @default.
• W2083722579 hasOpenAccess W2083722579 @default.
• W2083722579 hasPrimaryLocation W20837225791 @default.
• W2083722579 hasRelatedWork W1747184343 @default.
• W2083722579 hasRelatedWork W1941768181 @default.
• W2083722579 hasRelatedWork W2020302560 @default.
• W2083722579 hasRelatedWork W2032692004 @default.
• W2083722579 hasRelatedWork W2096917975 @default.
• W2083722579 hasRelatedWork W2307524438 @default.
• W2083722579 hasRelatedWork W2374988073 @default.

• next